Results

Total Results: 2,209 records

Showing results for "drug".

201. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/juvenile-arthritis-dmards/research
     September 26, 2011 - There are few direct comparisons of DMARDs, and insufficient evidence to determine if any specific drug … or drug class has greater beneficial effects.

202. Comparative Effectiveness and Safety of New Therapies (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/diabetes-glucose-control_research.pdf
     July 01, 2010 - We evaluated whether early use of this drug was consistent with the FDA-approved indications for use … The dataset included patients with a diagnosis of DM, or a claim for a drug used to treat DM, between … (San Diego, CA), was approved by the FDA on April 28, 2005.2 Exenatide is a first-in-class drug that … If the patient had sufficient drug-on-hand for 2 Effective Health Care Program Research Report … Discussion The early users of this new drug (in the first six months since approval) were largely

203. Who Uses Exenatide For Glucose Control in Diabetes Mellitus? A Retrospective Cohort Study of a New Therapy | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/diabetes-glucose-control/research
     August 04, 2010 - Health, Department of Epidemiology Abstract Background: Exenatide was approved by the Food and Drug … We evaluated whether early use of this drug was consistent with the FDA-approved indications for use. … The dataset included patients with a diagnosis of DM, or a claim for a drug used to treat DM, between … (San Diego, CA), was approved by the FDA on April 28, 2005. 2 Exenatide is a first-in-class drug that … , he was considered to have been on this drug for that interval.

204. Nonopioid Pharmacologic Treatments for Chronic Pain | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/nonopioid-chronic-pain/research
     June 21, 2022 - We evaluated effect modification through subgroup and sensitivity analyses, including specific drug, … Increased incidence of drug class–specific adverse events led to withdrawal from treatment in some patients … , suggesting that careful consideration of patient characteristics is needed in selecting nonopioid drug

205. Cancer Chemotherapy | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/cancer-chemotherapy
     August 20, 2024 - Chemotherapy is drug therapy for cancer.

206. PEPTIC ULCER #11 (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/peptic-ulcer-horizon-scan-high-impact-1506.pdf
     June 01, 2015 - Drug Enforcement Administration. … The drug was subsequently studied for its potential to reduce IBS symptoms, such as diarrhea. … Food and Drug Administration (FDA) for treating diarrhea-predominant IBS. … Some experts believe that concerns about overuse of antibiotics might limit the use of the drug. … Food and Drug Administration (FDA); 2015 May 27 [accessed 2015 Jun 03]. [5 p].

207. Methamphetamine | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/methamphetamine
     Methamphetamine Description Methamphetamine - meth for short - is a very addictive stimulant drug … mouth" - broken teeth and dry mouth Thinking and emotional problems NIH: National Institute on Drug

208. Inhalants | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/health-topics/inhalants
     NIH: National Institute on Drug Abuse Source https://medlineplus.gov/inhalants.html

209. Rheumatoid-Arthritis-Medicine Surveillance (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/rheumatoid-arthritis-medicine_surveillance.pdf
     March 01, 2013 - CER #55: Drug Therapy for Rheumatoid Arthritis in Adults: An Update Original release date: April … Introduction Comparative Effectiveness Review (CER) #55, Drug Therapy for Rheumatoid Arthritis in … This drug is not a biologic. … Drug Therapy for Rheumatoid Arthritis in Adults: An Update. … Risk did not differ significantly by specific drug.

210. Rheumatoid-Arthritis-Medicine Surveillance (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/rheumatoid-arthritis-medicine_surveillance.pdf
     March 01, 2013 - CER #55: Drug Therapy for Rheumatoid Arthritis in Adults: An Update Original release date: April … Introduction Comparative Effectiveness Review (CER) #55, Drug Therapy for Rheumatoid Arthritis in … This drug is not a biologic. … Drug Therapy for Rheumatoid Arthritis in Adults: An Update. … Risk did not differ significantly by specific drug.

211. Methods-Guidance-Reporting-Bias Methods (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/methods-guidance-reporting-bias_methods.pdf
     November 01, 2013 - Food and Drug Administration. … Drug Approval Process Manufacturers are required to submit a New Drug Application to the FDA for all … The Drugs@FDA site may be searched by the generic or trade drug name (not drug class) for Statistical … Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication … Drug Effectiveness Review Project.

212. S149 (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/s149.pdf
     October 01, 2007 - that uses subclassification on a longitudinal pro- pensity score to compare outcomes between a new drug … We explored the usefulness of these methods in our study of a new drug for treatment of type 2 diabetes … The median date for first filling a pre- scription for this drug was mid-October 2005. … Because the drug was only recently approved, we had limited follow-up time. … Additionally, when studying a new drug, it is even less clear what are the predictors of use of the drug

213. rheumatoid-arthritis-medicine-update-protocol-170515 (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/rheumatoid-arthritis-medicine-update_research-protocol.pdf
     May 15, 2017 - Published online: May 15, 2017 Evidence-based Practice Center Systematic Review Protocol Project Title: Drug … However, data on disease-modifying antirheumatic drug (DMARD) use in the first 3 months are limited. … Food and Drug Administration; RA = rheumatoid arthritis; TNF = tumor necrosis factor; ts = targeted … Choosing a RA treatment drug can be difficult with these populations. … Drug Therapy for Rheumatoid Arthritis in Adults: An Update [Internet].

214. Finding Grey Literature Evidence and Assessing for Outcome and Analysis Reporting Biases When Comparing Medical Interventions: AHRQ and the Effective Health Care Program | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/methods-guidance-reporting-bias/methods
     November 18, 2013 - Food and Drug Administration. … Drug Approval Process Manufacturers are required to submit a New Drug Application to the FDA for all … The Drugs@FDA site may be searched by the generic or trade drug name (not drug class) for Statistical … Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and … Drug Effectiveness Review Project.

215. Horizon Scanning_Rapid Cost Analyses of Selected Potential High-Impact Intervention Reports (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/horizon-scan_research-2015.pdf
     January 01, 2015 - Food and Drug Administration (FDA) status of products subject to FDA regulation at the time the cost … health benefit a drug provides for a specific indication. … Whether these initiatives will alter drug pricing is unclear at this time, although Dr. … million to $180 million per year in costs of this new drug for the labeled indication. … Food and Drug Administration (FDA).

216. Disposition of Comments Report for CER 134 Pharmacotherapy for Adults With Alcohol-Use Disorders in Outpatient Settings (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/alcohol-misuse-drug-therapy_disposition-comments.pdf
     May 13, 2014 - J Stud Alc Drug Dependence. 2012;73 (6):991-997 Thank you for the comment. … longitudinal care coordinated by a primary care clinician with no CCM for people with alcohol or drug … As I said before, if they take the drug at the right dose, it is unlikely that drinking will occur. … J Stud Alc Drug Dependence. 2012;73 (6):991-997. 5. Dunbar JL, Tumcliff RZ, Dong Q, et al. … Only if a trial recruited more patients that responded to drug A than drug B would you get a difference

217. Addressing Knowledge Gaps in Type 2 Diabetes Therapeutics: Comparative Effectiveness and Safety of Oral Antidiabetic Drugs | Effective Health Care (EHC) Program
     effectivehealthcare-admin.ahrq.gov/products/diabetes-oral-drugs-safety-knowledge-gaps/research
     January 01, 2005 - Pharmacoepidemiol Drug Saf 2011;20:36-44. Huizinga MM, Roumie CL, Greevy RA, et al. … Pharmacoepidemiol Drug Saf 2010;19:1108-12. Hung AM, Roumie CL, Greevy RA, et al.

218. Making Healthcare Safer IV: Summary of Findings, 2023-2024 (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/mhs-IV-1-year-final-report-updated-title_0.pdf
     May 01, 2024 - Computerized Clinical Decision Support To Prevent Medication Errors and Adverse Drug Events ........ … Reducing Adverse Drug Events Related to Anticoagulant Use in Adults 9a. … involving CDSS to reduce medication errors and adverse drug events. … Computerized Clinical Decision Support To Prevent Medication Errors and Adverse Drug Events 1a. … Reducing Adverse Drug Events Related to Anticoagulant Use in Adults 9a.

219. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/thromboembolism-update-executive-170622.pdf
     June 01, 2017 - (aspirin) versus VKA (2 RCTs, one NRCS), LMWH versus antiplatelet drug (2 NRCSs), antiplatelet drug … versus FXaI (1 RCT), antiplatelet drug versus mechanical devices (1 RCT, 1 NRCS), antiplatelet drug … drug and mechanical device; LMWH alone versus combinations of LMWH and antiplatelet drug, DTI, FXaI … drug, UFH, and mechanical device. … Across this study set, 12 classes were evaluated (antiplatelet drug [aspirin], antiplatelet drug plus

220. Venous Thromboembolism Prophylaxis in Major Orthopedic Surgery: Systematic Review Update (pdf file)
     effectivehealthcare-admin.ahrq.gov/sites/default/files/thromboembolism-update-executive-170622.pdf
     June 01, 2017 - (aspirin) versus VKA (2 RCTs, one NRCS), LMWH versus antiplatelet drug (2 NRCSs), antiplatelet drug … versus FXaI (1 RCT), antiplatelet drug versus mechanical devices (1 RCT, 1 NRCS), antiplatelet drug … drug and mechanical device; LMWH alone versus combinations of LMWH and antiplatelet drug, DTI, FXaI … drug, UFH, and mechanical device. … Across this study set, 12 classes were evaluated (antiplatelet drug [aspirin], antiplatelet drug plus